Key Metrics of Kairos Pharma Ltd.
Revenue—FY 2023
Operating income−$1.7M
Net profit−$1.8M
Shareholders' equity−$2.1M
Market cap$1.8MKAPA · $0.54
Competitors10identified
About Kairos Pharma Ltd.
Sectors
Company details
- Founded
- 2024
- Listed
- NYSE: KAPA (since 2024)
Operational Areas of Kairos Pharma Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameKairos Pharma Ltd.
TickerKAPA
ExchangeNYSE
CountryUnited States
SEC CIK0001962011
Listed since2024
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
KAPA · NYSE · SEC CIK 0001962011
Last price · 31 Oct 2026
$0.54
+3.25%
Market cap$1.8M
P/E—On FY 2023 diluted EPS
Volume123,055
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPO—Listed 2024
KAPA share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Kairos Pharma Ltd.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Similar companies
B
BeOne Medicines Ltd.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Summit Therapeutics Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
ICON plc (ICLR)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
J
Jazz Pharmaceuticals plcPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Charles River Laboratories International Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
Ascendis Pharma A/S Ordinary SharePharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medpace Holdings Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
Insmed IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.